Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederroche.com
Get the latest updates from Investor Update directly as they happen.
Follow now 351 followers
Last updated 27 days ago
27 days ago
Susvimo is the only continuous delivery treatment to provide reliable, long-term vision...
about 1 month ago
Trontinemab’s Phase Ib/IIa Brainshuttle™ AD study continues to show rapid and robust...
about 1 month ago
EMA’s CHMP issued an opinion not to recommend Elevidys™ (delandistrogene moxeparvovec) for...
about 1 month ago
The Roche Investor Relations team would like to invite you to the...
about 1 month ago
Group sales grew by 7%1 at constant exchange rates (CER; 4% in...
about 1 month ago
Elecsys pTau181 is the first In Vitro Diagnostic Regulation (IVDR) certified test...
about 1 month ago
Approval based on INAVO120 data showing the Itovebi™ (inavolisib)-based regimen more than...
about 1 month ago
Participation certificates (Partizipationsscheine) with a nominal value of CHF 0.001 each will...
about 1 month ago
The pivotal phase IIb ALIENTO study met the primary endpoint of a...
about 1 month ago
Basel, 18 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced...
about 1 month ago
Roche will publish its Half Year Results of 2025 prior to the...
2 months ago
Roche will publish its Half Year Results of 2025 prior to the...